New Agreements Underscore QIAGEN's Leadership in Bioinformatics

Feb 02, 2016, 16:05 ET from QIAGEN NV

HILDEN, Germany and AARHUS, Denmark, February 2, 2016 /PRNewswire/ --

FDA centers and researchers gain access to QIAGEN's enhanced solutions for applications including microbial and microbiome analysis

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced new partnerships to enhance the profile and expand the use of its market leading bioinformatics solutions for microbiome, metagenomics and other applications.

QIAGEN Bioinformatics signed an agreement with genomics big data company CosmosID, Inc. to allow users of QIAGEN's CLC Genomics Workbench to access and integrate CosmosID's metagenomics analysis platform into their QIAGEN bioinformatics platform. CosmosID's platform allows users to identify and characterize microbial communities from whole genome shotgun data and to determine their relative abundance. The new plug-in expands the range of metagenomic and microbiome applications supported by QIAGEN's microbial genomics solution enabling researchers in fields such as infectious disease, animal health, agriculture, environmental and food safety to use shotgun metagenomics analysis for routine testing employing next-generation sequencing.

Click here for full press release

Public Relations: Dr. Thomas Theuringer Director Public Relations +49-2103-29-11826 +1-240-686-7425 Email: pr@qiagen.com http://www.twitter.com/qiagen https://www.facebook.com/QIAGEN pr.qiagen.com

Investor Relations: John Gilardi Vice President Corporate Communications and Investor Relations +49-2103-29-11711 +1-240-686-2222 Email: ir@qiagen.com

SOURCE QIAGEN NV